CAR T NKR-2: leveraging the breadth of innate immunity – FierceBiotech
|
CAR T NKR-2: leveraging the breadth of innate immunity
FierceBiotech Cell-based immunotherapy employs specially modified T-cells to recognize and destroy tumor cells. Chimeric antigen receptor (CAR) T-cells recognize tumor antigens with high specificity, and the technique has achieved considerable success in the … |
